BridgeBio Pharma, Inc. (BBIO) Social Stream
BRIDGEBIO PHARMA INC (BBIO) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering BRIDGEBIO PHARMA INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-05 | 8 | $88 | $68 | $79.625 | $37.69 | 111.26% |
| 2021-12-03 | 8 | $88 | $66 | $79.375 | $37.69 | 110.6% |
| 2022-01-18 | 8 | $86 | $17 | $41.125 | $37.69 | 9.11% |
| 2022-02-24 | 8 | $86 | $17 | $40.875 | $37.69 | 8.45% |
| 2022-02-28 | 8 | $80 | $17 | $33.857 | $37.69 | -10.17% |
| 2022-03-08 | 7 | $80 | $17 | $32 | $37.69 | -15.1% |
| 2022-03-15 | 7 | $80 | $17 | $31.857 | $37.69 | -15.48% |
| 2022-04-13 | 7 | $80 | $17 | $31.571 | $37.69 | -16.24% |
| 2022-05-05 | 7 | $80 | $17 | $32.142 | $37.69 | -14.72% |
| 2022-05-18 | 6 | $27 | $17 | $23.166 | $37.69 | -38.54% |
| 2022-05-24 | 7 | $27 | $17 | $22.571 | $37.69 | -40.11% |
| 2022-06-13 | 7 | $27 | $12 | $20.428 | $37.69 | -45.8% |
| 2022-06-17 | 7 | $27 | $13 | $20.571 | $37.69 | -45.42% |
| 2022-07-26 | 7 | $27 | $17 | $21.285 | $37.69 | -43.53% |
| 2022-08-13 | 7 | $30 | $17 | $21.714 | $37.69 | -42.39% |
| 2022-09-17 | 8 | $30 | $17 | $21.875 | $37.69 | -41.96% |
| 2022-11-03 | 8 | $26 | $17 | $21 | $37.69 | -44.28% |
| 2022-11-08 | 8 | $24 | $17 | $20.75 | $37.69 | -44.95% |
| 2022-11-11 | 8 | $24 | $16 | $20.5 | $37.69 | -45.61% |
| 2022-11-18 | 8 | $24 | $16 | $20.375 | $37.69 | -45.94% |
| 2023-01-06 | 8 | $24 | $15 | $20.25 | $37.69 | -46.27% |
| 2023-01-26 | 9 | $24 | $15 | $19.75 | $37.69 | -47.6% |
| 2023-02-08 | 9 | $24 | $12 | $19.375 | $37.69 | -48.59% |
| 2023-02-24 | 9 | $23 | $14 | $19.375 | $37.69 | -48.59% |
| 2023-02-27 | 9 | $23 | $15 | $19.375 | $37.69 | -48.59% |
| 2023-03-06 | 9 | $26 | $17 | $20.5 | $37.69 | -45.61% |
| 2023-03-08 | 9 | $29 | $18 | $24 | $37.69 | -36.32% |
| 2023-04-05 | 9 | $29 | $18 | $24.375 | $37.69 | -35.33% |
| 2023-04-13 | 9 | $29 | $18 | $25 | $37.69 | -33.67% |
| 2023-05-08 | 10 | $40 | $18 | $26.875 | $37.69 | -28.69% |
| 2023-06-15 | 9 | $40 | $18 | $27.875 | $37.69 | -26.04% |
| 2023-07-17 | 9 | $49 | $24 | $31.75 | $37.69 | -15.76% |
| 2023-07-18 | 10 | $49 | $26 | $36.625 | $37.69 | -2.83% |
| 2023-08-01 | 10 | $50 | $33 | $44.555 | $37.69 | 18.21% |
| 2023-08-04 | 10 | $50 | $33 | $44.777 | $37.69 | 18.8% |
| 2023-08-17 | 10 | $60 | $33 | $45.444 | $37.69 | 20.57% |
| 2023-09-06 | 10 | $60 | $33 | $46.111 | $37.69 | 22.34% |
| 2023-09-25 | 10 | $60 | $33 | $45.888 | $37.69 | 21.75% |
| 2023-10-25 | 10 | $60 | $33 | $47 | $37.69 | 24.7% |
| 2023-11-12 | 10 | $60 | $28 | $46.666 | $37.69 | 23.82% |
| 2023-12-07 | 10 | $60 | $28 | $46.333 | $37.69 | 22.93% |
| 2023-12-08 | 10 | $60 | $28 | $47.666 | $37.69 | 26.47% |
The Trend in the Analyst Price Target
Over the past 19 months, BBIO's average price target has gone up $15.52.
Over the past 46 weeks, BBIO's average upside potential has been 63.11%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-26 | 8 | 24 | 15 | 19.750 | 8.85 | 123.16% |
| 2023-03-13 | 9 | 29 | 18 | 24.375 | 14.53 | 67.76% |
| 2023-08-14 | 10 | 60 | 33 | 45.888 | 31.55 | 45.45% |
| 2023-09-06 | 10 | 60 | 33 | 46.111 | 29.49 | 56.36% |
| 2023-11-23 | 10 | 60 | 28 | 46.333 | 29.50 | 57.06% |
BBIO Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.2 | 9 | 0 | 1 | 0 | 0 | 10 |
The Trend in the Broker Recommendations
Over the past 22 months, BBIO's average broker recommendation rating worsened by 0.1.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BBIO as an investment opportunity.
- In the context of all US stocks, BRIDGEBIO PHARMA INC's upside potential (average analyst target price relative to current price) is greater than 984.29% of them.
- In terms of how BRIDGEBIO PHARMA INC fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -2300.69% of that group.
- BBIO has a higher average analyst price target than 2268.08% of stocks in the mid market cap category.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, BRIDGEBIO PHARMA INC's number of analysts covering the stock is greater than 3060.74% of them.
In the Pharmaceutical Products industry, MORF, ARVN, and YMAB are the three stocks most similar to BRIDGEBIO PHARMA INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for BBIO? Use POWR Ratings for clearer insight into price direction.